A Common Polymorphism Renders the Luteinizing Hormone Receptor Protein More Active by Improving Signal Peptide Function and Predicts Adverse Outcome in Breast Cancer Patients | Zendy

Djura Piersma | Zendy; Els M.J.J. Berns | Zendy; Miriam VerhoefPost | Zendy; André G. Uitterlinden | Zendy; Ineke Braakman | Zendy; Huibert A. P. Pols | Zendy; Axel P. N. Themmen | Zendy

Open Access

A Common Polymorphism Renders the Luteinizing Hormone Receptor Protein More Active by Improving Signal Peptide Function and Predicts Adverse Outcome in Breast Cancer Patients

Author(s) -

Djura Piersma,

Els M.J.J. Berns,

Miriam VerhoefPost,

André G. Uitterlinden,

Ineke Braakman,

Huibert A. P. Pols,

Axel P. N. Themmen

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-2156

Subject(s) - breast cancer , medicine , endocrinology , estrogen , estrogen receptor , biology , breast disease , cancer , oncology

Epidemiological and animal studies indicate a carcinogenic role of estrogens in breast tissue. The pituitary gonadotropin LH is an important regulator of estrogen production in premenopausal women, whereas even in women after menopause, 10-25% of ovarian steroid hormone production is LH dependent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research